<DOC>
	<DOCNO>NCT02243241</DOCNO>
	<brief_summary>Evaluate effect multiple dos ( daily 3 day HYD 80 , 120 , 160 mg tablet ) QT/QTc interval .</brief_summary>
	<brief_title>The Effect Hydrocodone Bitartrate ( HYD ) Extended-Release Tablets QT /QTc Intervals Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Provide write informed consent ; Body weight range 50 100 kilogram ( kg ) [ 110 220 pound ] body mass index ( BMI ) 18 30 ( kg/m2 ) ; Males females age 18 50 year ; Willing eat food supply study ; Willing refrain strenuous exercise endofstudy visit . Subjects begin new exercise program participate unusually strenuous physical exertion ; Healthy free significant abnormal finding determine medical history , physical examination , clinical laboratory value , vital sign , safety 12lead ECG ; Females childbearing potential must use adequate reliable method contraception ( ie , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ) . Females postmenopausal must postmenopausal â‰¥ 1 year elevate serum follicle stimulate hormone ( FSH ) . Females pregnant ( positive beta human chorionic gonadotropin test ) lactating ; Current recent ( within 5 year ) history drug alcohol abuse ; History current condition may interfere drug absorption , distribution , metabolism , excretion ; Use opioidcontaining medication past 30 day precede initial dose study ; Known allergy hydrocodone , opioids , psychotropic hypnotic drug , moxifloxacin , member quinolone class drug ; Any history frequent nausea emesis regardless etiology ; Any history seizure head trauma sequela ; Participation clinical drug study 30 day precede initial dose study drug study ; Use medication include thyroid hormonal therapy ( hormonal contraception hormonal replacement therapy form estrogen without progestin allow ) , vitamin , herbal and/or mineral supplement 7 day precede initial dose study drug ; Any significant illness 30 day precede initial dose study drug study ; Any personal family history prolong QT interval disorder cardiac rhythm ; Abnormal cardiac condition include hypertension ; Abnormal cardiac condition denote follow : QT data correct heart rate use Fridericia formula ( QTcF ) interval &gt; 450 millisecond ( msec ) PR interval &gt; 240 msec QRS &gt; 110 msec Evidence second thirddegree atrioventricular block Pathological Qwaves ( define Qwave &gt; 40 msec depth &gt; 0.5 millivolt [ mV ] ) Evidence ventricular preexcitation , complete leave bundle branch block ( LBBB ) , right bundle branch block ( RBBB ) , incomplete RBBB With rest heart rate ( HR ) outside range 40 90 beat per minute ( bpm ) ; Abnormalities physical examination , vital sign , safety 12lead ECG , clinical laboratory value , unless abnormality judge clinically insignificant investigator ; Oxygen saturation &lt; 94 % measure pulse oximetry ( SpO2 ) ; Refusal abstain completely caffeine xanthine confinement ; Refusal abstain consumption alcoholic beverages 48 hour prior initial study drug administration endofstudy visit ; Blood blood product donate within 30 day prior initial study drug administration time endofstudy visit , except require study protocol ; History smoking use nicotine product within 45 day initial study drug administration positive urine cotinine test ; Positive result urine drug screen alcohol screen ; Positive result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( antiHCV ) ; Presence Gilbert 's Syndrome know hepatobiliary abnormality ; The investigator believe subject unsuitable reason ( ) specifically state exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Opioid</keyword>
	<keyword>ECG</keyword>
	<keyword>QTcI</keyword>
</DOC>